QR-Code

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates between 20% and 60%, a...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2026-02-01
Schriftenreihe:Molecular Oncology
Schlagworte:
acute myeloid leukemia
azacitidine
AZD4573
venetoclax
Online-Zugang:https://doi.org/10.1002/1878-0261.70124
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge